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Abstract   
The impact of complement on cancer metastasis has not been well studied. In this 
report, we demonstrate in a preclinical mouse model of breast cancer that the 
complement anaphylatoxin C5a receptor (C5aR) facilitates metastasis by suppressing 
effector CD8+ and CD4+ T cell responses in the lungs. Mechanisms of this suppression 
involve recruitment of immature myeloid cells to the lungs and regulation of TGF-β and 
IL-10 production in these cells. TGF-β and IL-10 favored generation of T regulatory cells 
(Treg) and Th2 oriented responses that rendered CD8
+ T cells dysfunctional. Importantly, 
pharmacological blockade of C5aR or its genetic ablation in C5aR-deficient mice were 
sufficient to reduce lung metastases. Depletion of CD8+ T cells abolished this beneficial 
effect, suggesting that CD8+ T cells were responsible for the effects of C5aR inhibition. 
In contrast to previous findings, we observed that C5aR signaling promoted Treg 
generation and suppressed T cell responses in organs where metastases arose. 
Overall, our findings indicated that the immunomodulatory functions of C5aR are highly 
context dependent. Furthermore, they offered proof-of-concept for complement-based 
immunotherapies to prevent or reduce cancer metastasis. 
Introduction 
Preventing cancer metastasis is a Holy Grail of cancer therapy, as the majority of 
cancer deaths are attributed to this process (1). However, progress in this area has 
been limited by our poor understanding of its mechanism. Recent evidence has 
indicated that, in addition to the mechanisms operating in neoplastic cells (2), alterations 
in host homeostasis, particularly in the immune system, contribute to metastasis (3). 
These alterations occur in the primary tumor microenvironment (2), however roles for 
3 
 
host-derived cells and mediators at sites distal to the tumor have also been reported (4). 
An important concept in tumor metastasis is the formation of premetastatic niches, in 
which malignant tumors prepare the environment of remote organs to receive metastatic 
cells by altering host homeostasis in these organs prior to tumor cell arrival. Since these 
changes precede metastases, therapeutic targeting of these premetastatic niches might 
prevent metastasis. The existence of premetastatic niches was proposed over a 
hundred years ago (3), but only recently have components of these niches been 
identified and they include myeloid-derived suppressor cells (MDSCs) (5-8). The 
primary tumor hypoxia inducible factors (9), serum amyloid A3 induced by S100A8 and 
A100A9 (10), and S1PR1-STAT3 signaling (11) have been suggested to be involved in 
recruiting these cells from the bone marrow to premetastatic organs. However, 
mechanisms governing recruitment of various cells to premetastatic organs and how the 
cells facilitate metastases are not clear. It is conceivable that MDSCs, which suppress 
anti-tumor T cell responses in primary tumors and peripheral lymphoid organs (12), 
shield metastasizing tumor cells from immune attack at distant sites targeted by 
metastases (5). However, in contrast to primary sites, the significance of T cell 
suppression in premetastatic niches remains unclear (13). Since the complement 
anaphylatoxin C5a, a potent chemoattractant in inflammatory reactions (14), activates 
and attracts immunosuppressive cells to primary tumors (15),  we hypothesize that C5a 
also contributes to immunosuppression facilitating metastases in distant sites.  
Using a mouse model of breast cancer (16), we show that C5a receptor 1 (C5aR) 
contributes to metastasis by suppressing T cell responses in the lungs, since reduction 
in metastatic burden in the lungs by C5aR-inhibition was abolished by CD8+ T cell  
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depletion. C5aR blockade resulted in increased recruitment of CD4+ and CD8+ T cells 
and induction of Th1/Tc1-biased T cell responses. Mechanisms of C5aR-mediated 
immunosuppression involved recruitment of MDSCs and generation of Treg cells and 
regulating production of the immunosuppressive cytokines, TGF-β and IL-10, in myeloid 
cells. Relevance of our findings for human breast cancer was underscored by identifying 
MDSCs and complement deposition in tumor draining lymph nodes (TDLNs) of breast 
cancer patients. 
 
Materials and Methods 
Mice and cell lines 
Balb/c wild-type (WT) and C5aR-deficient (C5aR-/-) mice were from The Jackson 
Laboratory. C5aR-/- mice were backcrossed ten generations to Balb/c before being 
made homozygous. Upon arrival to The Jackson Laboratory, these mice were bred at 
least one generation to Balb/c.  Mice were housed in the animal facility of Texas Tech 
University Health Sciences Center (TTUHSC). Water and standard rodent diet were 
provided ad libitum. All experiments were approved by the Committee of Institutional 
Animal Care and Use according to the guidelines of the National Institutes of Health. 
4T1 (CRL-2539, ATCC) and 4T1-luc2-GFP (128090, Caliper/PerkinElmer) tumor cell 
lines were maintained in cell culture media as recommended by suppliers and routinely 
tested for the absence of mycoplasma (Aldevron, ND, USA). The information of tumor 
model development and CD8+ T cell depletion is provided in supplemental materials. 
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Complement C5a receptor antagonism 
A selective antagonist of C5aR, the cyclic peptide Ac-(cyclo-2,6)-F[OP(D-
Cha)WR] was used for C5aR-blockade. This compound, originally named 3D53 and 
also licensed as PMX53 (17) but abbreviated as C5aRA herein, specifically binds to 
C5aR1 and does not bind to the second C5a receptor (C5L2) or to the C3a receptor 
(18). It was synthesized and characterized as described (19), dissolved in sterile PBS, 
and injected s.c. at a dose of 1 mg/kg body weight, every 2–3 days beginning on day 7 
after tumor cell injection (3.3 μmol/kg body weight per week) (15); or day 12-15 after 
4T1-luc2-GFP cell injection when palpable breast tumors (approximately 5 mm in 
diameter) were observed. The delay in administering C5aRA when 4T1-luc2-GFP cells 
were injected in mice was due to the slower tumor growth compared to the parent 4T1 
cell line. Control mice received sterile PBS.  
Tissue and cell processing, immunofluorescence/immunohistochemistry, 
quantitative PCR, ELISA for complement fragments, and bronchoalveolar lavage 
isolation 
Mouse organs were fixed in 10% (v/V) formalin, 4% paraformaldehyde or froze in 
optimum cutting temperature (O.C.T) medium. Formalin fixed samples were routinely 
processed for histology and immunohistochemistry. Paraformaldehyde-fixed lungs were 
immersed in 30% sucrose, washed in PBS, and then froze in O.C.T. medium. Frozen 
samples were sectioned with cryostat (Leica) for immunofluorescence or quantification 
of GFP+ metastases. Blood samples after erythrocyte lysis with ACK buffer (118-156-
101, Quality Biological), were stained for FACS. Lungs were digested in the digestion 
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buffer (collagenase D) and mechanically disintegrated and passed through 40 µm cell 
strainers (BD Biosciences) to obtain single-cell suspensions. Spleens were 
mechanically disintegrated and passed through cell strainers. Formalin fixed sections 
were stained with hematoxylin & eosin (H&E) to quantify metastases by digital 
pathology algorithms. Details of immunofluorescence/immunohistochemistry 
procedures, information on scoring metastases, quantitative PCR, C5a and C3 ELISA, 
Bronchoalveolar lavage (BAL) isolation, are provided in supplemental materials. 
Antibodies, functional assays, and FACS 
For T cell stimulation assays, cells were incubated in the presence of brefeldin-A 
and monensin (BD Biosciences) in CD3 and CD28 antibodies adsorbed 96-well plates 
(17A2 and 37.51, eBioscience) for 6 to 8 h. Cytokine production was assessed by 
intracellular cytokine staining. For analysis of C5aR expression, cells were incubated 
with rabbit polyclonal anti–mouse C5aR (C1150-32; BD Biosciences) or rabbit isotype-
matched control antibody (550875; BD Pharmingen) and then with FITC–conjugated 
anti-rabbit IgG (F0112; R&D Systems). In addition, rat mAb to mouse C5aR (20/70; 
Hycult Biotechnology) or rat isotype-matched control antibody (553928; BD 
Pharmingen), followed by FITC–conjugated anti–rat IgG (81–9511; Zymed-Invitrogen) 
were used.  
 To study the impact of C5aR-signaling in MDSCs on the polarization of T cell 
responses, groups of tumor-bearing Balb/c WT mice were injected with C5aRA or PBS 
as described in supplemental materials. On day 30, mouse lungs were harvested for 
MDSCs isolation, which was performed with MDSC isolation kit (miltenyi). Naïve CD4+ T 
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cells were negatively sorted (miltenyi) from splenocytes of non-tumor-bearing mice. 
Purity of cells was verified by FACS staining and found to be >98%. CD4+ T cells and 
lung-derived MDSCs were co-cultured in 1:5 ratios in a 24-well plate previously coated 
with CD3/CD28 antibodies. CD4+ T cell cultures were harvested at day 5 and 
intracellular staining for IFN-γ and IL-4 was performed after stimulation as described in 
supplemental materials. Additional information on antibodies, staining and gating 
strategies is also provided in supplemental materials.    
Digital image analysis 
 H&E stained lung and liver sections were scanned and digitalized (Aperio 
Technologies, Inc.). Quality control of digital whole slide images (WSI) and all further 
analysis were performed using ImageScope (Aperio). Aperio Genie Classifier was used 
for analyzing all the WSI.  
Statistical analysis  
 At least five mice per group were included in each experiment, except one 
experiment with n=3. Data were analyzed with un-paired t-test or non-parametric Mann-
Whitney test, depending on results of the normality test (Kolmogorov-Smirnov). For data 
with the normal distribution two-tailed un-paired t-test (t-test) was used. Two-tailed un-
paired t-test with Welch’s correction (t-test with Welch’s correction) was used for data 
having significant differences in variances between groups. For data lacking the normal 
distribution two-tailed non-parametric Mann-Whitney (Mann-Whitney test) test was 
used. For multiple comparisons One-way ANOVA and for normalized data from qPCR 
one sample t-test were used. Outliers were identified using Grubb’s test at α=0.05. All 
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statistical analysis was done with Graph Pad Prism 6 software. Statistical significance 
was based on a value of P≤0.05. For P>0.05, 95% confidence interval (CI) was used to 
draw conclusions. 
Results 
C5aR signaling facilitates lung and liver metastases 
 C5aR-signaling was found to promote tumor growth by modulating anti-tumor 
immunity in a syngeneic mouse model of cervical cancer (15). However, its role in 
metastatic spread of cancer has not been explored. Therefore, we investigated whether 
C5aR contributes to metastasis.  We found that C5aR deficiency reduced lung (Fig. 1A, 
B) and liver (Supplemental Fig. S1A, B) metastatic burden without significantly affecting 
the growth of primary breast tumors (Fig. 1C) in a syngeneic model of breast cancer 
(4T1), which closely mimics stage IV of human breast cancer (16). Decreased 
metastatic burden together with the lack of an impact of C5aR-deficiency on primary 
tumor growth suggests that C5aR promotes metastasis through mechanisms 
independent of those operating in primary tumors.  In addition, since 4T1 tumor cells do 
not express C5aR (Supplemental Fig. S1C), C5aR-signaling in tumor cells does not 
directly govern metastasis to distant organs. To support our data from genetically 
modified mice, we examined the impact of pharmacological inhibition of C5aR on 
metastases in mice bearing GFP-expressing 4T1 breast tumors (4T1-GFP+). Metastatic 
burden was markedly reduced in mice treated with C5aR antagonist (C5aRA) compared 
to placebo treated control mice (Fig. 1D-F). Importantly, 75% of the mice that received 
C5aRA remained metastases-free (Fig. 1E), while 25% of the mice developed fewer 
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and smaller lung metastases than control mice (Fig. 1E, F). Despite this substantial 
impact on metastasis, similar to observations from the experiments with C5aR knockout 
mice, pharmacological inhibition of C5aR by C5aRA did not affect growth of the primary 
tumors in this study (Fig. 1G).  
C5aR inhibits the recruitment and function of CD4+ and CD8+ T cells in the lungs 
and livers of breast tumor-bearing mice 
 Anti-tumor CD4+ and CD8+ T cells are considered to be major effectors that limit 
tumor growth at primary sites and our previous study linked C5aR to anti-tumor T cell 
responses (15). However, no role for T cells in preventing metastases at distal organs 
has been demonstrated. Therefore, we examined the impact of C5aR blockade on both 
of these T cell populations. We found higher numbers of CD4+ and CD8+ T cells in the 
peripheral blood (Fig. 2A, E) and higher percentages of these cells in the lungs of breast 
tumor-bearing mice treated with C5aRA compared to control mice (Fig. 2B, F). A similar 
observation was made in C5aR-/- mice (data not shown). We hypothesize that these 
cells, which were found to be more frequent in C5aR-/- or C5aRA treated mice, would 
also be more efficient in the immunosurveillance of the distant organs, eventually 
contributing to reduction in metastatic burden. This hypothesis is supported by 
significantly higher percentages of IFN-γ producing CD4+ and CD8+ T cells observed in 
the lungs of C5aRA treated or C5aR-/- mice when stimulated ex vivo with CD3/CD28 
antibodies (Fig. 2C, G, D, H). Thus, we propose that the absence of C5aR-signaling 
encompasses Th1 and Tc1 predominant responses, which are likely to be involved in 
the clearance of circulating and/or seeding tumor cells in the lungs. This is further 
supported by significantly higher numbers of perforin-armed CD8+ T cells infiltrating the 
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lungs of breast tumor-bearing mice that received C5aRA (Fig. 2I, J), supporting 
contribution of these cells to protection of this organ against metastasizing tumor cells, 
since acquisition of perforin is a major effector function of CD8+ cytotoxic T cells (CTL) 
and these cells posses tumoricidal activity (20). The impact of C5aR signaling on T cell 
accumulation in metastases-targeted organs appears to be indirect, as we did not 
detect any expression of C5aR on peripheral blood CD4+ and CD8+ T cells 
(Supplemental Fig. S1D). Next, we examined expression of CXCR-3 and LFA-1 on 
CD8+T cells in peripheral blood of breast tumor-bearing mice treated with C5aRA and 
PBS, since these receptors are involved in the homing of effector CD8+T cells to the 
lungs in other models (21-23). However, we found no differences in the expression of 
these receptors (data not shown). Similar to the lungs, an increased accumulation of 
CTLs was observed in the livers of C5aR-/- mice compared to Balb/c WT mice 
(Supplemental Fig. S1E, F).  
To confirm that reduction in metastatic burden caused by C5aR inhibition was 
dependent on the protective role of CD8+ T cells, we investigated the impact of C5aR 
inhibition on lung metastases in mice with depleted CD8+ T cells. C5aR blockade did 
not reduce lung metastases in these mice (Fig. 2K). On the contrary, in mice with an 
intact CD8+ T cell population treated with control IgG, we observed a protective effect of 
C5aRA treatment, with a significant reduction in the lung metastatic burden compared to 
control mice (Fig. 2K). This observation indicates that C5aR inhibits the protective 
function of CD8+ T cells in metastasis-targeted organs rendering them unable to control 
metastasis. 
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C5a regulates the immunosuppressive environment of metastases-targeted 
organs 
 The accumulation of immunosuppressive myeloid cells has been reported to be a 
contributing factor in the formation of premetastatic sites, thereby facilitating metastasis 
(5, 6). However, factors regulating the recruitment of these cells to distant sites need to 
be elucidated. In our previous study in a model of HPV-induced cancer, we 
demonstrated that C5a acts as a potent chemoattractant of MDSCs to the primary 
tumors (15). Thus, we hypothesized that C5a/C5aR also activates and recruits MDSCs 
to premetastatic niches, resulting in immunosuppression in metastases targeted organs 
prior to tumor cell arrival. In fact, genetic (Fig. 3A) and pharmacological (Fig. 3B, C) 
ablation of C5aR decreased MDSC infiltration of the lungs of breast tumor-bearing mice 
(Fig. 3A, B, C). A similar reduction in MDSCs was observed in the livers of C5aR-/- mice 
(Supplemental Fig. S1 G, H). We did not find any differences in the numbers of MDSCs 
present in peripheral blood (Supplemental Fig. S2 A) and bone marrow (Supplemental 
Fig. S2 B) of C5aRA-treated and control mice. In an independent set of experiments, we 
determined that tumor cells were first observed in the lungs between days 20 to 26 after 
injection of 4T1 cells (Supplemental Fig. S2 C), whereas a significant increase in MDSC 
infiltration into the lungs could be detected at day 16 (Supplemental Fig. S2 D, E). 
Interestingly, we observed that complement activation, which is associated with C5a 
generation, occurred in the lungs of breast tumor-bearing mice prior to metastases and 
significant accumulation of MDSC (Fig. 3D), since complement C3 fragments were 
deposited in the lungs as early as at day 4 after tumor implantation (Fig. 3D). Therefore, 
we propose that in premetastatic niches, C5a functions as a chemoattractant for 
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MDSCs expressing high levels of C5aR (Fig. 3E).  This hypothesis is supported by the 
presence of high amounts of C5a in peripheral blood of breast tumor-bearing mice, 
which increased at later time points (Supplemental Fig. S3A). Although we observed 
some increases in C5a levels in BAL, these differences did not reach statistical 
significance (data not shown). Interestingly, we also found increases in total C3 
concentration in plasma (Supplemental Fig. S3B) and BAL (Supplemental Fig. S3C) 
suggesting enhanced production of complement fragments in tumor-bearing mice. 
Increased expression of genes encoding C3 and C5 in the liver (Supplemental Fig. 
S3D) indicated that this organ is a primary site of C3 and C5 production in tumor-
bearing mice. In contrast, we did not observe increased expression of C3 and C5 in the 
lungs (data not shown).  Importantly, we did not find enhanced deposition of C3 
cleavage fragments and increased expression of C3 and C5 genes (data not shown) in 
the kidneys that are usually spared from metastasis in this tumor model (16). We 
observed deposition of some C3 cleavage fragments limited to the periphery of kidney 
glomeruli in tumor-free mice with identical staining pattern  as reported previously (24). 
The presence of primary breast tumors did not increase this deposition (Supplemental 
Fig. S3E), indicating that enhanced complement activation is limited to organs targeted 
by metastasis.   
Since immunosuppressive properties of MDSC in the primary tumor 
microenvironment are maintained to a large extent by cytokines produced in these cells 
(25), we investigated whether similar mechanisms operated in premetastatic niches. 
The impact of C5aR inhibition on the expression of cytokines involved in 
immunosuppression, such as IL-10, and TGF-β, was evaluated in lung myeloid cells of 
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tumor-bearing mice. We determined numbers of cells that produced only one of the 
examined cytokines, as well as cells that co-expressed both cytokines. Total lung cells 
were isolated from breast tumor-bearing mice treated with C5aRA or PBS and 
stimulated ex vivo with the TLR4 agonist lipopolysaccharide (LPS). We found reduction 
in the amount of CD11b+ cells producing only TGF-β in mice treated with C5aRA 
compared to the PBS group (Fig. 3F). Relatively low numbers of cytokine-producing 
cells were observed in total lung cells. Of note, extremely rare hematopoietic stem 
cell/progenitors have found to be key contributors to the premetastatic niche (7). 
Importantly, we found that C5aR inhibition reduced numbers of CD11b+ cells that co-
produced TFG-β and IL-10 (Fig. 3G). TGF-β and IL-10, in addition to facilitating 
metastasis (26, 27), are also reported to promote Treg cell generation (28, 29), thereby 
suppressing adaptive immunity in the tumor microenvironment (25). Therefore, we next 
assessed whether decreased production of these cytokines in mice treated with C5aRA 
correlated with the reduced numbers of Treg cells in the lungs of mice with primary 
breast tumors. We found that these mice had lower numbers of Treg cells compared to 
control mice (Fig. 3H). This finding was consistent with a reduction in the numbers of 
Treg cells in the circulation (Fig. 3I). Thus, we propose that C5aR signaling contributes to 
immunosuppression in metastases-targeted lungs via recruitment of MDSCs to these 
sites, regulation of TGF-β and IL-10 expression in these cells and, consequently, 
generation of Treg cells.  
C5aR in MDSCs affects T cell polarization in metastases-targeted organs 
 We observed that C5aR-deficiency led to Th1 polarization of CD4+ T cells in the 
lungs of breast tumor-bearing mice (Fig. 4A). To confirm that C5a impacts generation 
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and polarization of anti-tumor effector T cell responses in metastases-targeted organs 
by modulating functions of MDSCs, CD4+ T cells isolated from spleens of tumor-free 
“naïve” mice were differentiated in vitro by stimulating with CD3/CD28 antibodies in the 
presence of lung-derived MDSCs (CD11b+Gr-1+) from control or C5aRA-treated breast 
tumor-bearing mice. Importantly, we observed by FACS analysis that these T cells 
lacked C5aR expression on their surface, excluding the possibility of a direct action of 
C5aRA on T cells (Supplemental Fig. S1D). We found that CD4+ T cells differentiated in 
the presence of lung MDSCs from C5aRA-treated mice displayed increased expression 
of IFN-γ, resulting in a higher Th1/Th2 ratio compared to a similar setting that used lung 
MDSC from the PBS group (Fig. 4B, C). Based on these data, we propose that C5aR 
signaling contributes to the polarization of CD4+ T cells to a Th2 type in the lungs of 
tumor-bearing mice by modulating MDSC functions and that disabling C5aR signaling 
reverses this effect. 
Inflammatory changes in the premetastatic niche resemble interstitial pneumonia-
like inflammation  
 In addition to the decrease in metastatic burden and decreased MDSC infiltration 
into the lungs and liver, C5aR-deficiecy (C5aR-/-) markedly attenuated inflammation in 
these organs. This was demonstrated by reduced inflammatory infiltrates in intra-
alveolar septa in the lungs (Fig. 5A), as well as in periportal areas of the liver (Fig. 5 B).  
Morphologic heterogeneity in these infiltrates suggests that, apart from MDSCs, other 
cells contribute to premetastatic niche formation and recruitment of these cells could be 
C5aR-dependent. A detailed histopathological evaluation revealed progressive 
inflammatory changes in the intra-alveolar septa of mice bearing tumors. This 
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inflammation acquired an interstitial ‘pneumonia-like’ pattern in advanced stages (Fig. 
5C). The diffuse interstitial infiltrates in the lungs were composed of cells resembling 
granulocytes, with an admixture of small lymphocytes and histiocytes. Occasionally, 
immature myeloid cells were noted (Fig. 5D).  
In the next set of experiments, we verified that inflammatory alterations of the 
lungs, observed prior to metastasis in the breast tumor-bearing mice, facilitated seeding 
of these organs by circulating tumor cells. In these experiments, mice were injected with 
regular 4T1 cells into the mammary fat pad to create premetastatic niche in the lungs, 
then these mice and tumor-free control mice were injected i.v. with 4T1-GFP+ (GFP-
expressing) cells. This experimental approach was used to investigate whether lung 
inflammation associated with, and induced by, the primary breast tumor could facilitate 
lung seeding by circulating GFP+ 4T1 cells (injected i.v.). Colonization of lungs by 
circulating tumor cells is reported to depend upon existence of a premetastatic niche. 
We observed that lung inflammation in tumor-bearing mice increased seeding of 4T1-
GFP+ cells in this organ, evident from higher numbers and increased sizes of GFP+ 
metastases in the lungs of mice previously injected with regular 4T1 into the mammary 
fat pad  (Fig. 5E, F, G, H). Nevertheless, GFP- (non-fluorescent) metastases were also 
present in these mice (Fig. 5E) but, by using animal imaging combined with fluorescent 
microscopy, we were able to distinguish GFP+ from GFP- metastases. When these 
experiments were repeated with 10-fold lower numbers of 4T1-GFP+ cells injected i.v., 
only mice bearing breast tumors developed GFP+ metastases in their lungs (Fig. 5I), 
indicating that circulating tumor cells required prior inflammatory changes in the 
premetastatic niche before effective lung seeding. 
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Complement deposition associated with MDSC recruitment may contribute to 
premetastatic niche formation in breast cancer patients 
To determine the clinical significance of our findings, sections of TDLNs from 
breast cancer patients with invasive, not-otherwise specified (NOS), ductal carcinoma 
were examined for infiltration by MDSCs and for complement activation (Fig. 6A, B). In 
these experiments, MDSCs were identified by co-expression of CD11b+ and CD33+ and 
complement deposition was analyzed as C3 cleavage product deposition (Fig. 6A, B). 
We found accumulation of MDSCs in the TDLNs with breast tumor metastases, as well 
as in those that were free of metastases, suggesting a correlation with and possible 
involvement of MDSCs in formation of premetastatic niches in humans. We observed 
C5aR-expression in those areas occupied by MDSCs (Supplemental Fig. S3F). 
Moreover, complement activation in the TDLNs was observed as extracellular 
deposition of C3 cleavage fragments in the vasculature and sinuses of these lymph 
nodes (Fig. 6B). In addition, we observed production of C3 in the macrophages located 
in sinuses, as demonstrated by intracellular staining (Fig. 6B). Intriguingly, both 
complement deposition and local production of C3 appeared to be higher in the TDLNs 
where metastases were present (Fig. 6B, right panels vs. left panels).  
Discussion 
  The role of complement in cancer remains uncertain with only a few studies to 
date reporting on tumor-promoting or tumor-inhibiting properties of complement proteins 
(30). Recent studies have provided some, albeit limited, mechanistic insights into the 
roles of certain complement proteins in cancer progression. For example, C5a 
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overexpression in tumor cells has been linked to tumor regression in a mouse model of 
breast cancer (31). Conversely, C5a has also been shown to promote progression of 
cancer in a model of cervical cancer through the recruitment of MDSCs to tumors (15). 
The activation of MDSC in the tumor microenvironment by C5aR leads to production of 
reactive oxygen and nitrate species that inhibit anti-tumor T cell responses (12, 15, 32).  
These findings placed C5a among inflammatory mediators implicated in the progression 
of cancer (33). In addition, recent work in a transgenic model of ovarian cancer has 
shown the contribution of complement to angiogenesis in ovarian tumors. In the 
absence of complement factor C3 or C5aR, the transgenic mice either did not develop 
ovarian tumors or the growth of tumors was significantly limited (34). 
Our present study reveals a new role for C5a and C5aR in tumor metastasis. We 
propose that C5a/C5aR signaling contributes to an inflammatory condition that creates 
a premetastatic niche environment by recruiting and facilitating generation of 
immunosuppressive cells in the lungs and livers of mice with breast malignancy. Recent 
studies have identified some key components of premetastatic niches and potential 
mechanisms that are involved in tumor cell recruitment to distal sites targeted by 
metastases (5, 7, 8, 10). However, considering that several other factors may be 
involved in this process, regulation of premetastatic niche environment and its role in 
metastases requires further elucidation. It is for example not known why different types 
of tumor cells home to different organs (35). Although accumulation of 
immunosuppressive MDSCs cells in a premetastatic niche was previously 
demonstrated, the precise mechanism governing this recruitment and the role of 
immunosuppression in facilitating metastases remain unclear (13). The present study 
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addresses this gap in knowledge of the properties of premetastatic niches. Furthermore, 
the roles of effector T cells in preventing metastasis at distant sites remain unknown. To 
our knowledge, this is the first report demonstrating that blockade of C5aR signaling 
enables CD8+ T cells to control lung metastases. In addition, our study suggests a 
protective nature for Th1/Tc1 polarized CD4+/CD8+ T cells in the context of lung 
metastasis. These findings have important therapeutic implications, as they provide 
proof of concept that boosting type 1 CD4+ T cell and CTL responses, with 
simultaneous targeting of the mechanisms of immunosuppression, can prevent 
metastases even at an advanced stage of cancer.  
In addition, given the abundance of complement fragments in plasma and 
interstitial fluid and their function in maintaining immune homeostasis (36), the 
contributions of complement C5a/C5aR signaling to premetastatic inflammation 
described herein points to a previously unknown mechanism for metastasis, which can 
operate at various locations. This is further supported by ubiquitous production of  
complement fragments by virtually all cells in the body participating in the innate 
immune responses, thus accessibility of complement proteins in most of the tissues is 
very high (36). Complement activation can also occur in vitro, for instance, complement 
components were secreted when CD4+ T cells were co-cultured with dendritic cells (37, 
38), indicating that formation of immunological synapses between proximal immune 
cells is sufficient enough to produce and activate complement fragments. Our data has 
shown that activation of complement in lungs of mice occurred as early as day 4 after 
injection of tumor cells and was associated with high concentrations of C5a in plasma. 
We observed an increase in C3 concentrations in plasma and BAL indicating increased 
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production of C3. In addition, we found a significant increase in C3 and C5 mRNA levels 
in the liver after 4T1 tumor inoculation. Therefore, we conclude that an increased 
concentration of complement fragments in the circulation of tumor-bearing mice is a 
consequence of increased production in the liver. This rapid onset of activation of the 
complement cascade is an upstream regulator of the premetastatic niche. C5a 
generated in this cascade leads to recruitment of MDSCs to the lungs prior to 
metastases. This function of C5a is similar to its role in recruiting leukocytes to sites of 
inflammation (14). Given ubiquitous expression of C5aR on cells of myeloid-origin, other 
myeloid cells in addition to MSDCs are also likely to be recruited to the premetastatic 
lungs. Interestingly, the morphological pattern of lung infiltration resembled that of 
interstitial pneumonia with most of the infiltrating cells present in the intra-alveolar septa. 
This type of pneumonitis in humans is difficult to diagnose based on physical 
examination, however, chest x-ray showing diffuse alveolar opacities or computerized 
tomography may provide diagnostic clues to premetastatic inflammation.  
In addition to recruiting MDSCs, C5a/C5aR signaling stimulated TGF-β and IL-10 
production in these cells. Since co-expression of TGF-β and IL-10 contributes to Treg 
cell generation upon antigenic stimulation (29), we speculate that C5aR signaling in 
recruited MDSCs regulates this process in premetastatic sites. Our data contrast with 
recent studies demonstrating inhibitory functions of C5aR in Treg cell generation (38, 
39). This “discordance” is consistent with immunomodulatory functions of C5aR being 
highly context dependent. In contrast to our study, the previous work was conducted in 
non-tumor models (38-40). In addition, some studies focused on thymus-derived 
(natural) Treg cells (39) that are generated through different pathways compared to 
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inducible Treg cells (41, 42). It appears that primary tumors alter the immune 
microenvironment, including the cytokine milieu, to such an extent that C5aR signaling 
in tumor-bearing mice has opposing roles to those in non-tumor models. Our previous 
work in a model of HPV-induced cancer has shown that C5aR inhibits antitumor T cell 
responses, although this study has examined roles of C5aR only in primary tumors and 
not at sites distal to the tumors (15).  
Inhibitory roles of complement in Treg cell generation have also been suggested 
in a transgenic model of ovarian cancer (34). Although MDSCs have been shown to 
increase Treg cell generation (43) and Treg cells and MDSCs are known for their 
immunosuppressive properties in the primary tumors (44), roles of these cells at the 
sites targeted by metastases have not been demonstrated. We propose that MDSCs 
and Treg cells have similar functions in metastases-targeted organs and work together to 
shield metastasizing tumor cells from immune attack. Indeed, reduction in MDSCs and 
Treg cells in the lungs of mice with breast tumors treated with C5aRA was associated 
with CD4+ and CD8+ T cell responses that resulted in reduced metastasis to the lungs. 
The lack of impact of C5aR inhibition on metastases in mice that were devoid of CD8+ T 
cells demonstrated that C5aR signaling facilitates metastasis by suppressing CD8+ T 
cell responses. Moreover, considering that type 1 CD4+ T cell responses are helpful in 
generating anti-tumor CD8+ T cell responses in the primary tumor microenvironment, we 
analyzed CD4+ T cell function in the lungs of breast tumor-bearing mice. We observed 
that disabling C5aR signaling augments IFN- and lowers IL-4 expression in CD4+ T 
cells in the lungs of mice compared to the control group. Further, to prove that the 
difference in T cell polarization was attributed to recruitment of MDSC, experiments 
21 
 
were conducted to differentiate “naïve” CD4+ T cells into effectors in the presence of 
lung MDSC isolated from C5aRA treated and control mice. These studies suggested 
that C5aR blockade in MDSCs increased numbers of IFN-γ-expressing CD4+ T cells 
and reduced numbers of IL-4 producing CD4+ T cells. Thus, by using in vitro co-culture 
experiments, we demonstrated that C5a/C5aR affects CD4+ T cell polarization through 
the modulation of MDSC functions. Nonetheless, besides improving the functional 
quality of T cells, C5aR blockade also resulted in increased recruitment of these cells to 
the lungs.  
The expression of C5aR on T cells remains controversial, with conflicting reports 
on C5aR expression in T cells (45). We did not detect C5aR expression on CD4+ and 
CD8+ T cells. Therefore, we propose an indirect regulation of T cell responses in the 
lungs through C5aR. C5aR inhibition did not affect expression of CXCR-3 and LFA-1 on 
circulating T cells, suggesting that increased T cell homing to the lungs is less likely to 
be responsible for increased numbers of T cells in the lungs of mice lacking C5aR or 
treated with C5aRA. A more plausible explanation is that reduction in MDSCs, caused 
by the lack C5aR signaling, decreases apoptosis and increases survival of T cells, as 
recent studies have shown that MDSCs promote T cells apoptosis (46). Importantly, 
effects of C5aR inhibition on metastasis and anti-tumor immunity appear to be 
independent from mechanisms operating in primary tumors, as this inhibition did not 
significantly affect growth of tumors in this breast tumor model. This finding, which 
contrasts with our previous report (15), can be attributed to the higher rate of tumor 
growth in a breast cancer model compared to the model used previously or simply to 
the difference in tumor type. The 4T1 tumors were on average three times larger 
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between day 25 and 27 (time of sacrifice in the current study) after injection of tumor 
cells, in comparison to TC-1 tumors in the previous study. We assumed that in a case of 
4T1 breast tumors, therapy introduced just two weeks before mice were sacrificed was 
unable to reduce growth of these aggressive tumors.  
In conclusion, this study provides evidence for the role of C5a/C5aR signaling in 
promoting metastasis via immunosuppression in premetastatic sites. Importantly, 
pharmacological blockade of this receptor efficiently activated adaptive immune 
responses and reduced lung metastatic burden. Given that the C5aR antagonist used in 
this study has already progressed to phase 2 clinical trials for inflammatory diseases  
(17, 47), this report builds an early foundation for introducing C5aR antagonism as a 
possible means of reducing risk of cancer metastasis in future clinical studies. 
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Figure legends 
Figure 1. C5aR signaling promotes metastasis to the lungs of breast tumor-
bearing mice. Scans of hematoxylin and eosin (H&E) stained sections of the lungs of 
wild-type (WT) and C5aR-deficient (C5aR-/-) mice with breast tumors (upper panels) and 
their corresponding digital mark-up images (lower panel), metastases-purple, tissue with 
severe inflammatory changes-red, and remaining tissue-yellow and pink colorations (A). 
Quantification of lung metastases from A, *P=0.0421 (t-test) (B).   Breast tumor volumes 
of WT and C5aR-/- mice at various time points after tumor cell injection (C). GFP+ 
metastases in the lungs of tumor-bearing mice treated with PBS or C5aR antagonist 
(C5aRA), arrow points to small metastatic tumor (D). Number of lung metastases, 
*P=0.0225 (Mann Whitney test) (E), and area covered by these metastases *P=0.0141 
(Mann Whitney test) (F), in PBS and C5aRA-treated tumor-bearing mice. Breast tumor 
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volumes of WT Balb/c mice treated with C5aRA or PBS at various time points after 
injection of tumor cells (G). Horizontal lines represent mean in scatter plots (C, E-G). 
Bars represent mean + s.e.m. Data are representative of two independent experiments 
with n1=19, n2=10 (A-C), or two independent experiments with n1≥8, n2=10 (D-G).  
Figure 2. C5a receptor blockade enhances CD4+ and CD8+ T cell responses. CD4+ 
T cells from peripheral blood, *P=0.0358 (t-test) (A), and lungs, *P=0.2452, with 95% 
confidence interval (CI) -0.08 to 0.30 (t-test) (B), of breast tumor-bearing mice iγnjected 
with PBS or C5aR antagonist (C5aRA). IFN-γ expressing CD4+ T-cells from lungs of 
breast tumor-bearing mice injected with PBS or C5aRA, *P=0.0368 (t-test) (C), and WT 
and C5aR-/- mice, *P=0.0004 (t-test) (D). CD8+ T cells from peripheral blood, *P=0.0267 
(t-test) (E), and lungs of breast tumor-bearing mice injected with PBS or C5aRA, 
*P=0.0471(t-test) (F). IFN-γ expressing CD8+ T cells from lungs of breast tumor-bearing 
mice injected with PBS and C5aRA, *P=0.1438, 95% CI -0.01 to 0.002 (t-test) (G), and 
WT and C5aR-/- mice *P=0.0364 (Mann Whitney test) (H). Perforin-expressing (red 
fluorescence) CD8+ (green fluorescence) T cells in lungs of breast tumor-bearing mice 
injected with PBS (left) or C5aRA (two right panels) (I), with quantification *P=0.0008 (t-
test) (J). Lung metastatic burden in Balb/c WT mice treated with C5aRA or PBS and 
injected with CD8-neutralizing antibody or isotype IgG, *P=0.0005 (Mann Whitney test), 
not significant (n.s) (K). CD8+ T cells in peripheral blood of Balb/c WT mice treated with 
PBS or C5aRA and injected with CD8-neutralizing antibody (α-CD8) or isotype IgG 
(Isotype), *P=0.0057 (Mann Whitney test), **P=0.0040 (t-test with Welch’s correction) 
(L). Scale bar 20 µm. Bars represent mean + s.e.m. Data are representative of two 
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independent experiments, n1=9 and n2=10 (A, B, C, F, G) or three independent 
experiments n1=8, n2=9 and n3=10 (E), or one experiment with at least n=8 (D-H, I-L).  
Figure 3. C5aR-mediated immunosuppression in the lungs of breast tumor-
bearing mice. CD11b and Gr-1 expression, green and red fluorescence, respectively, in 
lung MDSCs of tumor-bearing wild-type (WT) and C5aR-/- mice (A), and tumor-bearing 
WT mice injected with PBS or C5aR antagonist (C5aRA) (B). MDSCs quantification, 
*P=0.0017 (t-test) from B (C). C3 cleavage products in the lungs of tumor-free and 
tumor-bearing mice (D). C5aR expression in CD11b+ blood cells in tumor-bearing mice 
(E). Percentages of CD11b+ cells expressing TGF-β after ex vivo LPS stimulation, 
*P=0.0085 (t-test with Welch’s correction) (F), and co-expressing TGF-β and IL-10, 
*P=0.0412 (t-test with Welch’s correction) (G) in the lungs of tumor-bearing mice 
injected with PBS or C5aRA. Percentages of Treg cells in the lungs, *P=0.2679, 95% CI -
0.001 to 0.005 (t-test) (H), and absolute counts of Treg cells in the peripheral blood, 
*P=0.05 (t-test) (I) of tumor-bearing mice injected with PBS or C5aRA. Blue 
fluorescence-DAPI (A, B, D). Bars represent mean + s.e.m.  Data are representative of 
one experiment with n=8 (A); or two independent experiments, n1≥8 and n2=10 (B, C, 
E); or two independent experiments, n1=3 and n2=8 (D); or one experiment, n=9 (F, G); 
or one experiment, n≥5 (H, I). Scale bar-100µm for A, B, 200µm for D, and 50µm for D. 
Figure 4. C5aR impacts T cell polarization by regulating lung MDSCs. Th1/Th2 
ratio calculated from IFN-γ (Th1)- and IL-4 (Th2)-expressing CD4+ T cells obtained from 
the lungs of breast tumor-bearing wild-type (WT) and C5aR-/- mice, *P=0.0245 (t-test 
with Welch’s correction) (A). Percentages of IFN-γ, *P=0.2712, 95% CI -0.02 to 0.06 (t-
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test) (B), and IL-4 expressing, *P=0.1332, 95% CI -60.23 to 10.18 (t-test with Welch’s 
correction) (C) CD4+ T cells differentiated in vitro by anti-CD3/CD28 stimulations in the 
presence of lung MDSCs from breast tumor-bearing mice treated with C5aRA or PBS. 
Horizontal lines represent mean + s.e.m. Data are representative of one independent 
experiment with n≥9 (A) and n≥5 (B, C). 
Figure 5. C5aR mediated inflammation facilitates metastases. Hematoxylin and 
eosin (H&E) stained sections of the lungs of wild-type (WT) and C5aR-/- tumor-bearing 
mice. Double-headed yellow arrows point to 54.92 µm in WT and 37.61 µm in C5aR-/- 
mice showing thickness of alveolar septa (A). H&E stained sections of the livers of WT 
and C5aR-/- tumor-bearing mice. Arrows point inflammatory cells (B). H&E stained 
sections of the lungs of tumor-free mice (left panel) and tumor-bearing mice (right panel) 
(C). Immature myeloid cells in H&E stained lung sections of tumor-bearing mice-arrows 
(D). The lungs from tumor-free (left panel) and tumor-bearing mice (right panel) injected 
i.v. with GFP+ tumor cells. Upper panel - white light images, note multiple gross 
metastases in breast tumor-bearing mice, lower panel - fluorescence images, arrows 
point to few GFP+ metastases in tumor-free mice, note numerous GFP+ metastases in 
breast tumor-bearing mice (E). GFP+ tumor cells (green fluorescence) in sections of the 
lungs of tumor-free (upper panel) and tumor-bearing mice (lower panel) injected i.v. with 
GFP+ tumor cells (F). Numbers of GFP+ metastases in the lungs of tumor-free (TF) and 
tumor-bearing mice (TB) injected i.v. with GFP+ tumor cells, *P=0.0604, 95% CI -18.1 to 
0.5 (t-test) (G). Size (area) of GFP+ metastases in the lungs of TF & TB mice injected 
i.v. with GFP+ tumor cells, *P=0.0159 (Mann Whitney test) (H). Bars represent mean + 
s.e.m. Scans of the end-point H&E stained lung sections from TF (left image) and TB 
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mice (middle image) injected i.v. with GFP+ tumor cells. Arrows point to metastases. 
Inset depicts the enlarged lung area with metastases. Right image- 
immunohistochemistry detection of GFP in lung metastases (I). Data are representative 
of two independent experiments with n1=5 and n2=6 (A, B, and E-I), or two independent 
experiments with n1=3 and n2=8 (C, D). Scale bars-100µm except 50 µm for D. 
Figure 6. MDSC infiltration and C3 deposition and expression in lymph nodes 
(LN) of breast cancer patients. Immunohistochemistry detection of human MDSC 
markers CD11b (brown) and CD33 (fast red) in axillary lymph nodes with (LN+) or 
without (LN-) breast cancer metastases. Yellow in digital mark-up images indicates cells 
that coexpress both CD11b and CD33 (A). Immunohistochemistry detection of C3/C3c 
in LN+ and LN-. Frames outline areas, which are shown in higher magnification in 
panels below. Arrowheads point to vessels with C3 cleavage product deposition, Arrows 
point to macrophages producing C3 (B). Scale bars-200μm for (A); 400μm, 200μm, and 
50μm for B upper, middle, and lower panel respectively. Data are representative of 12 
patients diagnosed with breast non-otherwise specified (NOS) ductal carcinoma with 
axillary lymph node metastases (six patients) and without axillary lymph node 
involvement (six patients) (A, B). 
 






